• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 10:35:16 AM ET
    $HLXA
    Business Services
    Finance
    Get the next $HLXA alert in real time by email
    SC 13G 1 form-sc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 (Amendment No._N/A_)*

     

    Helix Acquisition Corp.

     

    (Name of Issuer)

     

    Class A Ordinary Shares

     

    (Title of Class of Securities)

     

    G4444C102

     

    (CUSIP Number)

     

    December 31, 2020

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. G4444C102  

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      RTW Investments, LP
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
       
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware, United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0 
       
    6. SHARED VOTING POWER
       
     

    750,000*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    750,000*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    750,000*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    6.29%*

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      PN, OO, IA

     

     
     

     

    CUSIP No. G4444C102  

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Roderick Wong
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
           
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
     

    750,000*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    750,000*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    750,000*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    6.29%

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IN, HC

     

     
     

     

    Item 1. (a).

    Name of Issuer:

         
        Helix Acquisition Corp.
         
      (b). Address of issuer’s principal executive offices:
         
        c/o Cormorant Asset Management, LLP, 200 Clarendon Street, 52nd Floor

        Boston, MA 02116
         
    Item 2. (a). Name of person filing:
         
        RTW Investments, LP
        Roderick Wong
         
      (b). Address or principal business office or, if none, residence:
         
        RTW Investments, LP
        40 10th Avenue
        Floor 7
        New York, New York 10014
         
        Roderick Wong
        c/o RTW Investments, LP
       

    40 10th Avenue

        Floor 7
        New York, New York 10014
         
      (c). Citizenship:
         
        RTW Investments, LP – Delaware
        Roderick Wong – United States of America
         
      (d). Title of class of securities:
         
        Class A Ordinary Shares
         
      (e). CUSIP No.:
         
        G4444C102

     

     
     

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      RTW Investments, LP:
         
      (a) [  ] Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) [  ] Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) [  ] Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) [X] Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) [  ] Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) [  ] Parent Holding Company or control person in accordance with §240.13d-1(b)(ii)(G)
      (h) [  ] Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) [  ] Church plan that is excluded from the definition of an investment company under §3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) [  ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J)
      (k) [  ] Group, in accordance with §240.13d-1(b)(ii)(K) (a) [  ]
         
      Roderick Wong:
         
      (a) [  ] Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) [  ] Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) [  ] Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) [  ] Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) [  ] Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) [X] Parent Holding Company or control person in accordance with §240.13d-1(b)(ii)(G)
      (h) [  ] Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) [  ] Church plan that is excluded from the definition of an investment company under §3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) [  ]   A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J)
      (k) [  ] Group, in accordance with §240.13d-1(b)(ii)(K) (a) [  ]

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
           
      (a) Amount beneficially owned:
           
        RTW Investments, LP – 750,000*
        Roderick Wong – 750,000*
             
      (b) Percent of class:
           
        RTW Investments, LP – 6.29%*
        Roderick Wong – 6.29%*
           
      (c) Number of shares as to which the person has:
           
        (i) Sole power to vote or to direct the vote
             
            RTW Investments, LP – 0
            Roderick Wong – 0
             
        (ii) Shared power to vote or to direct the vote
             
            RTW Investments, LP – 750,000*
            Roderick Wong – 750,000*
             
        (iii) Sole power to dispose or to direct the disposition of
             
            RTW Investments, LP – 0
            Roderick Wong – 0
             
        (iv) Shared power to dispose or to direct the disposition of
             
            RTW Investments, LP – 750,000*
            Roderick Wong – 750,000*

     

     

     

    * The Class A Ordinary Shares (the “Shares”), of Helix Acquisition Corp. (the “Company”), reported herein are held by one or more private funds (together the “Funds”), which are managed by RTW Investments, LP (the “Adviser”). The Adviser, in its capacity as the investment manager of Funds, has the power to vote and the power to direct the disposition of all Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 750,000 Shares, or 6.29% of the Shares issued and outstanding as of December 3, 2020. Roderick Wong is the Managing Partner of the Adviser. The beneficial ownership percentage reported herein is based on 11,930,000 Shares issued and outstanding as of December 3, 2020, as disclosed in the Company’s Form 10-Q, as filed with the Securities and Exchange Commission on December 3, 2020. This report shall not be deemed an admission that the Adviser, the Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person’s pecuniary interest therein.

     

     

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

       
      N/A
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
    Item 10. Certification.
       
     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2021

       
         
      RTW Investments, LP
         
      By: /s/ Roderick Wong
        Roderick Wong, Managing Partner
         
      Roderick Wong
         
      By: /s/ Roderick Wong
        Roderick Wong, Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

       

     

    Get the next $HLXA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLXA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HLXA
    SEC Filings

    See more
    • SEC Form S-1/A filed by Helix Acquisition Corp. (Amendment)

      S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)

      7/26/22 8:43:13 AM ET
      $HLXA
      Business Services
      Finance
    • SEC Form S-1/A filed by Helix Acquisition Corp. (Amendment)

      S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)

      7/15/22 5:08:30 PM ET
      $HLXA
      Business Services
      Finance
    • Helix Acquisition Corp. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits

      8-K - MoonLake Immunotherapeutics (0001821586) (Filer)

      6/17/22 4:05:44 PM ET
      $HLXA
      Business Services
      Finance

    $HLXA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Helix Acquisition Corp.

      SC 13D - MoonLake Immunotherapeutics (0001821586) (Subject)

      4/18/22 4:49:17 PM ET
      $HLXA
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Helix Acquisition Corp. (Amendment)

      SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)

      2/14/22 2:35:06 PM ET
      $HLXA
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Helix Acquisition Corp. (Amendment)

      SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)

      2/14/22 6:12:44 AM ET
      $HLXA
      Business Services
      Finance

    $HLXA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sturge Simon

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      5/5/22 5:51:12 PM ET
      $HLXA
      Business Services
      Finance
    • SEC Form 4 filed by Xavier Ramnik

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      5/5/22 5:49:11 PM ET
      $HLXA
      Business Services
      Finance
    • SEC Form 4 filed by Moukheibir Catherine

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      5/5/22 5:47:33 PM ET
      $HLXA
      Business Services
      Finance

    $HLXA
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services

    $HLXA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab

       - Total proceeds expected to be approximately $230 million, combining funds held in Helix Acquisition Corp's trust account and a private investment in public entity (PIPE) financing - Leading institutional investors commit $115 million through a PIPE led by Cormorant Asset Management - Business combination is expected to be completed late in the fourth quarter of 2021 or early in the first quarter of 2022 - The combined company plans to advance clinical development of the tri-specific Nanobody® sonelokimab for the treatment of skin and joint diseases driven by IL-17A and IL-17F MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapi

      10/4/21 7:00:00 AM ET
      $HLXA
      Business Services
      Finance